BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Canagliflozin (alert removed 9/2020)

Lower Limb Ampution (Removed from Box Warning 8/18/2020)

  • An approximately 2-fold increased risk of lower limb amputations associated with INVOKANA use was observed in CANVAS and CANVAS-R, two large, randomized, placebo-controlled trials in patients with type 2 diabetes who had established cardiovascular disease (CVD) or were at risk for CVD.
  • Amputations of the toe and midfoot were most frequent; however, amputations involving the leg were also observed. Some patients had multiple amputations, some involving both limbs.
  • Before initiating, consider factors that may increase the risk of amputation, such as a history of prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers.
  • Monitor patients receiving INVOKANA for infection, new pain or tenderness, sores or ulcers involving the lower limbs, and discontinue if these complications occur

FDA and Industry Communications

Index to FDA Safety Information

Patient Counseling Information

Medication Guides

Patient Medication Guide

Package Inserts

Canagliflozin

Additional Information

Updated September 2020